You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Exploiting Natural Products-Based Therapeutics for Aflatoxin Mitigation

    SBC: CFD RESEARCH CORPORATION            Topic: CBD152003

    Aflatoxins are a paradigm among fungal produced mycotoxins that are present in food supplies and are strongly associated with increased risk forthe development of hepatocellular carcinoma. Currently, there are no known countermeasures that can selectively mitigate aflatoxin toxicity andthe available options are only symptomatic treatments. To meet this challenge, we propose to harness the microbio ...

    SBIR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  2. Long non-coding RNA signatures to classify multiple sclerosis

    SBC: IQuity Labs, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Diagnosis of multiple sclerosis MS rests on clinical symptoms and examinations supported by appropriate magnetic resonance imaging findings or other laboratory tests such as oligoclonal bands in cerebrospinal fluid and evoked potential testing Clinically isolated syndrome CIS is a first neurologic episode lasting at least hours possibly caused by focal ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Nitric oxide releasing nanomatrix wrap to enhance dialysis fistula maturation

    SBC: ENDOMIMETICS LLC            Topic: 400

    DESCRIPTION provided by applicant More than U S patients have end stage renal disease and over utilize hemodialysis as their renal replacement modality of choice The Achilles Heel in the care of dialysis patients is the development of a functioning and durable vascular access preferably an arteriovenous fistula The annual cost of treating vascular access dysfunction totals over ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A Next Generation, Low Cost Tracking System for Healthcare

    SBC: Q-Track Corporation            Topic: 600

    DESCRIPTION provided by applicant The goal of the Phase I study is to determine the feasibility of piloting a low cost Real Time Location System RTLS for use in healthcare based on a novel technology known as Near Field Electromagnetic The proposed QHealth system promises to support a number of healthcare applications such as equipment management workflow optimization hand hygiene complian ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Tumor Proliferation PET Tracer FLT using a Low Cost Single Dose Automatic Production and Quality Control Biomarker Generator System

    SBC: ABT Molecular Imaging            Topic: 102

    DESCRIPTION provided by applicant Worldwide a person dies from cancer every seconds Positron emission tomography PET is an effective tool that is critical in diagnosing cancer and monitoring treatment efficacy PET imaging relies on use of short lived radioisotopes Commercial distribution of the most commonly used radio tracer F FDG has resulted in patient population coverage in ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia

    SBC: DISCOVERYBIOMED, INC.            Topic: 200

    DESCRIPTION provided by applicant DiscoveryBioMed Inc DBM Inc or DBM specializes in normal and diseased human cell platform engineering DBM has assembled a consortium of experts whereby collectively we seek Fast Track SBIR funding to establish and offer a Product Line Menu of normal and ADPKD human cell platforms for the academic and industry marketplaces Existing and interested DBM ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance

    SBC: EXSCIEN CORPORATION            Topic: NIDDK

    DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A Predictive In Vitro Model for Screening Personalized Responses to CFTR-directed Therapeutics

    SBC: CFD RESEARCH CORPORATION            Topic: NHLBI

    Abstract The objective of this study is to develop a novel predictive in vitro model for personalized responses to CFTR directed therapeutics This proposal responds to RFA HL Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator Directed Therapeutics Cystic fibrosis CF is a life shortening genetic disease caused by loss of ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Chikungunya Recombinant Subunit Vaccine

    SBC: HAWAII BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Chikungunya virus CHIKV is an alphavirus classified as a category C priority pathogen that causes fever rash and arthralgia in humans In the past decade CHIKV outbreaks have spread beyond the endemic regions of Africa and Asia first to the islands in the Indian Ocean and most recently to the Americas The World Health Organization has reported that as ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government